JP2023539113A - フェネチルアミン誘導体、組成物およびその使用方法 - Google Patents
フェネチルアミン誘導体、組成物およびその使用方法 Download PDFInfo
- Publication number
- JP2023539113A JP2023539113A JP2023512107A JP2023512107A JP2023539113A JP 2023539113 A JP2023539113 A JP 2023539113A JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023539113 A JP2023539113 A JP 2023539113A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- substituted
- alkyl
- deuterium
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026037834A JP2026120523A (ja) | 2020-08-18 | 2026-03-10 | フェネチルアミン誘導体、組成物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067303P | 2020-08-18 | 2020-08-18 | |
| US63/067,303 | 2020-08-18 | ||
| US202063131974P | 2020-12-30 | 2020-12-30 | |
| US63/131,974 | 2020-12-30 | ||
| PCT/EP2021/072898 WO2022038171A1 (en) | 2020-08-18 | 2021-08-18 | Phenethylamine derivatives, compositions, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037834A Division JP2026120523A (ja) | 2020-08-18 | 2026-03-10 | フェネチルアミン誘導体、組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539113A true JP2023539113A (ja) | 2023-09-13 |
| JP2023539113A5 JP2023539113A5 (cg-RX-API-DMAC7.html) | 2024-07-26 |
Family
ID=77564095
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512107A Pending JP2023539113A (ja) | 2020-08-18 | 2021-08-18 | フェネチルアミン誘導体、組成物およびその使用方法 |
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2026037834A Pending JP2026120523A (ja) | 2020-08-18 | 2026-03-10 | フェネチルアミン誘導体、組成物およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2026037834A Pending JP2026120523A (ja) | 2020-08-18 | 2026-03-10 | フェネチルアミン誘導体、組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US12630504B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4200290A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2023539113A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20230053611A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021327136B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3186357A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2022038170A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| US12465578B2 (en) | 2021-09-25 | 2025-11-11 | Alexander Shulgin Research Institute, Inc. | Substituted alpha-ethyl phenylalkylamines |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023351134A1 (en) * | 2022-09-26 | 2025-05-08 | Alexander Shulgin Research Institute | 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminium chloride |
| JP2026513655A (ja) * | 2022-10-28 | 2026-04-30 | サイビン アイアールエル リミテッド | フェネチルアミン化合物、組成物、及び使用方法 |
| AU2024303691A1 (en) * | 2023-06-15 | 2026-01-08 | Tactogen Inc | New formulations for mental disorders or mental enhancement |
| WO2025228547A1 (en) | 2024-05-01 | 2025-11-06 | Cybin Irl Limited | Processes for preparing phenethylamine compounds |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198767A (ja) * | 1998-12-23 | 2000-07-18 | Bayer Ag | フッ素―含有フェネチルアミン類の製造法ならびに新規なフッ素―含有β―イミノビニル―及びβ―イミノエチルベンゼン類 |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| WO2008016677A2 (en) * | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| JP2008516974A (ja) * | 2004-10-15 | 2008-05-22 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン |
| WO2016040822A1 (en) * | 2014-09-12 | 2016-03-17 | Pinpoint Testing, Llc | Ready-to-constitute analytical platforms for chemical analyses and quantification |
| JP2020520358A (ja) * | 2017-05-18 | 2020-07-09 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Pge2レセプター調節剤としてのピリミジン誘導体 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6982348B2 (en) | 2001-01-26 | 2006-01-03 | Takeda Pharmaceutical Company Limited | Aminoethanol derivatives |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| WO2006079999A2 (en) | 2006-04-09 | 2006-08-03 | Barth Frederik H | Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
| CA2682432C (en) | 2007-03-30 | 2017-06-06 | Duke University | Device and method for delivery of a medicament |
| US20090318454A1 (en) | 2008-03-24 | 2009-12-24 | Weiner Carl P | Novel antioxidants and methods of treatment |
| CN107011313B (zh) | 2016-01-27 | 2021-11-30 | 天士力医药集团股份有限公司 | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 |
| US20190142851A1 (en) | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| US11723894B2 (en) | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| HUE066828T2 (hu) | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| CN112430187B (zh) | 2019-08-07 | 2023-01-17 | 北京奇点势能科技有限公司 | 一种α,β-氘代胺类化合物、氘代药物及其制备方法 |
| US11246860B2 (en) | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| EP4221682A2 (en) | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US20220267252A1 (en) | 2021-02-24 | 2022-08-25 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
| US20220323378A1 (en) | 2021-04-03 | 2022-10-13 | Shawn Joseph | Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity |
| WO2022221942A1 (en) | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prevention of drug diversion |
| WO2022225884A1 (en) | 2021-04-22 | 2022-10-27 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psychedelic compounds and uses thereof |
| JP2024520832A (ja) | 2021-06-08 | 2024-05-24 | エンセオジェニックス バイオサイエンシズ, インコーポレイテッド | セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 |
| US20240335401A1 (en) | 2021-06-23 | 2024-10-10 | Synaptive Therapeutics Llc | Substituted phenethylamine for treating inflammation and psychological disorders |
| WO2023283386A2 (en) | 2021-07-07 | 2023-01-12 | Arcadia Medicine, Inc. | Safer psychoactive compositions |
| AU2022311812A1 (en) | 2021-07-14 | 2023-08-24 | Altrartis Therapeutics Inc. | Novel short-acting psychoactive compounds of the mdma class |
| EP4387952A1 (en) | 2021-08-20 | 2024-06-26 | Terran Biosciences Inc. | Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof |
| AU2022342266B2 (en) | 2021-09-08 | 2026-03-26 | Cybin Irl Limited | Combination drug therapies |
| US12465578B2 (en) | 2021-09-25 | 2025-11-11 | Alexander Shulgin Research Institute, Inc. | Substituted alpha-ethyl phenylalkylamines |
| US20250236589A1 (en) | 2022-02-15 | 2025-07-24 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| AU2023222126A1 (en) | 2022-02-15 | 2024-08-08 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| US20250205198A1 (en) | 2022-03-31 | 2025-06-26 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| AU2023242469A1 (en) | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| JP2026513655A (ja) | 2022-10-28 | 2026-04-30 | サイビン アイアールエル リミテッド | フェネチルアミン化合物、組成物、及び使用方法 |
-
2021
- 2021-08-18 JP JP2023512107A patent/JP2023539113A/ja active Pending
- 2021-08-18 US US18/041,728 patent/US12630504B2/en active Active
- 2021-08-18 KR KR1020237006128A patent/KR20230053611A/ko active Pending
- 2021-08-18 AU AU2021327136A patent/AU2021327136B2/en active Active
- 2021-08-18 WO PCT/EP2021/072896 patent/WO2022038170A1/en not_active Ceased
- 2021-08-18 US US18/041,731 patent/US12122741B2/en active Active
- 2021-08-18 CA CA3186357A patent/CA3186357A1/en active Pending
- 2021-08-18 CA CA3186359A patent/CA3186359A1/en active Pending
- 2021-08-18 EP EP21763068.0A patent/EP4200290A1/en active Pending
- 2021-08-18 KR KR1020267007984A patent/KR20260044248A/ko active Pending
- 2021-08-18 AU AU2021328671A patent/AU2021328671B2/en active Active
- 2021-08-18 WO PCT/EP2021/072898 patent/WO2022038171A1/en not_active Ceased
- 2021-08-18 JP JP2023512063A patent/JP7802769B2/ja active Active
- 2021-08-18 EP EP21766581.9A patent/EP4200021A1/en active Pending
- 2021-08-18 KR KR1020237003815A patent/KR20230051486A/ko active Pending
-
2024
- 2024-09-05 US US18/825,122 patent/US20240425451A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185299A patent/JP2026041715A/ja active Pending
-
2026
- 2026-02-05 US US19/530,573 patent/US20260167603A1/en active Pending
- 2026-03-10 JP JP2026037834A patent/JP2026120523A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198767A (ja) * | 1998-12-23 | 2000-07-18 | Bayer Ag | フッ素―含有フェネチルアミン類の製造法ならびに新規なフッ素―含有β―イミノビニル―及びβ―イミノエチルベンゼン類 |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| JP2008516974A (ja) * | 2004-10-15 | 2008-05-22 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン |
| WO2008016677A2 (en) * | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| WO2016040822A1 (en) * | 2014-09-12 | 2016-03-17 | Pinpoint Testing, Llc | Ready-to-constitute analytical platforms for chemical analyses and quantification |
| JP2020520358A (ja) * | 2017-05-18 | 2020-07-09 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Pge2レセプター調節剤としてのピリミジン誘導体 |
Non-Patent Citations (11)
| Title |
|---|
| "RN 2112331-94-7他", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7025002336, 11 August 2017 (2017-08-11), ISSN: 0005609482 * |
| ACS CHEMICAL BIOLOGY, vol. 1, no. 12, JPN6025021753, 2006, pages 766 - 779, ISSN: 0005609481 * |
| CHEMISTRY & BIODIVERSITY, vol. 3, no. 3, JPN6025021749, 2006, pages 326 - 336, ISSN: 0005609473 * |
| FORENSIC SCIENCE INTERNATIONAL, vol. Vol. 170, No. 2-3, JPN6025021755, 2007, pages 100 - 104, ISSN: 0005609475 * |
| JOURNAL OF LABELLED COMPOUNDS AND RADIOPHAMACEUTICALS, vol. 33, no. 7, JPN6025021757, 1993, pages 645 - 654, ISSN: 0005609477 * |
| JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 50, no. 7, JPN6025021752, 2007, pages 660 - 665, ISSN: 0005609480 * |
| JOURNAL OF MASS SPECTROMETRY, vol. 46, no. 9, JPN6025021756, 2011, pages 865 - 875, ISSN: 0005609476 * |
| JOURNAL OF ORGANIC CHEMISTRY, vol. 84, no. 23, JPN6025021751, 2019, pages 15098 - 15105, ISSN: 0005609478 * |
| JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 147, JPN6025021750, 2017, pages 634 - 644, ISSN: 0005609474 * |
| PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 38, no. 3, JPN6025021748, 1991, pages 505 - 512, ISSN: 0005609472 * |
| THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 325, no. 3, JPN6025021758, 2008, pages 791 - 800, ISSN: 0005609479 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540017A (ja) | 2023-09-21 |
| CA3186359A1 (en) | 2022-02-24 |
| WO2022038171A1 (en) | 2022-02-24 |
| US20260167603A1 (en) | 2026-06-18 |
| KR20260044248A (ko) | 2026-04-01 |
| AU2021327136B2 (en) | 2025-12-18 |
| US20240317704A1 (en) | 2024-09-26 |
| KR20230053611A (ko) | 2023-04-21 |
| EP4200021A1 (en) | 2023-06-28 |
| US12122741B2 (en) | 2024-10-22 |
| US20240425451A1 (en) | 2024-12-26 |
| JP2026041715A (ja) | 2026-03-10 |
| WO2022038170A1 (en) | 2022-02-24 |
| CA3186357A1 (en) | 2022-02-24 |
| AU2021327136A1 (en) | 2023-02-16 |
| EP4200290A1 (en) | 2023-06-28 |
| KR20230051486A (ko) | 2023-04-18 |
| US12630504B2 (en) | 2026-05-19 |
| JP7802769B2 (ja) | 2026-01-20 |
| AU2021328671A1 (en) | 2023-02-16 |
| JP2026120523A (ja) | 2026-07-22 |
| US20230312464A1 (en) | 2023-10-05 |
| AU2021328671B2 (en) | 2026-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12630504B2 (en) | Phenethylamine derivatives, compositions, and methods of use | |
| AU2022342266B2 (en) | Combination drug therapies | |
| US20250145566A1 (en) | Phenethylamine derivatives, compositions, and methods of use | |
| US20250236589A1 (en) | Therapeutic phenethylamine compositions and methods of use | |
| AU2021276656A1 (en) | Deuterated tryptamine derivatives and methods of use | |
| KR20250097837A (ko) | 펜에틸아민 화합물, 조성물, 및 사용 방법 | |
| KR20250053871A (ko) | 트립타민 화합물, 조성물, 및 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240718 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240718 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250603 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250903 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260310 |